Dublin, June 25, 2018 (GLOBE NEWSWIRE) -- The "United States Generic Drugs Market, By Therapeutic Application [Central Nervous System (CNS), Cardiovascular, Dermatology, Genitourinary (GU)/Harmonal Drugs, Respiratory, Anti-infective, Oncology & Others], Companies" report has been added to ResearchAndMarkets.com's offering.

United States Generic Drugs Market is projected to exceed USD 210 Billion by 2024

United States Generic Drugs Market is so huge that nearly 80% of dispensing prescriptions accounts generic drugs. According to FDA in the United States 9 out of 10 prescriptions filled are for generic drugs. Most of the physicians and hospitals are now prescribing generic drugs than that of the brand-name drugs. Generic Drugs are those drugs which have same active component as patent drugs in same outline & equal amounts. Generic drugs are also called as Off-Label drugs.

The prime reason for the growth of United States Generic Drugs Market can be attributed to its pricing, on an average generic (Off-Label) drug is around 40-60% cheaper than those of Branded Drugs. However, this price of generic drug further declines, when various generic drug companies target a single approved drug, then market competition results in prices 85% less than the branded drugs. Also, increasing number of drug patent expirations, government initiatives and rising prevalence of chronic diseases are some other factors which are expected to propel the growth of United States Generic Drugs Market in the near future.

Key Topics Covered:

1. Executive Summary

2. United States Pharmaceutical Market
2.1 Branded Pharmaceutical Market
2.2 Generics Pharmaceutical Market

3. United States Generic Drugs Saving

4. Market Share - United States Pharmaceutical
4.1 Branded vs. Generics Drugs
4.2 Branded Generic vs. Unbranded Generic Drug
4.3 Volume Penetration - Generic vs. Branded Drugs
4.4 Therapeutic Application

5. United States Generic Drugs Market (2010 - 2024)
5.1 Branded Generic Drugs Market
5.2 Unbranded Generic Drugs Market

6. Therapeutic Application - United States Generic Drugs Market (2010 - 2024)
6.1 Central Nervous System (CNS)
6.2 Cardiovascular
6.3 Dermatology
6.4 Genitourinary / Hormonal Drugs
6.5 Respiratory
6.6 Anti-infective
6.7 Oncology
6.8 Others

7. Teva Pharmaceutical Industries Ltd - Company Analysis
7.1 Product Launch
7.2 Financial Insight

8. Mylan N.V. - Company Analysis
8.1 Product Launch
8.2 Financial Insight

9. Sandoz Inc. - Company Analysis
9.1 Product Launch
9.2 Financial Insight

10. Endo Pharmaceuticals - Company Analysis
10.1 Product Launch
10.2 Financial Insight

11. Lupin Limited - Company Analysis
11.1 Product Launch
11.2 Financial Insight

12. Dr Reddy's - Company Analysis
12.1 Business Portfolio
12.2 Financial Insight

13. Sun Pharmaceutical Industries Ltd. - Company Analysis
13.1 Product Launch
13.2 Financial Insight

14. Others
14.1 Financial Insight

15. Growth Driver
15.1 Rising Geriatric Population of United States
15.2 Generic Drugs Cost less than Brand Name Drugs
15.3 Rising Incidence of non-communicable Diseases

16. Challenges
16.1 Lack of Regulation & Information
16.2 Long Halt for Expiration of Patent Drug

For more information about this report visit https://www.researchandmarkets.com/research/vhx76q/united_states?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Generic Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.